Funder
Merck Serono
AstraZeneca
Bayer
Bayer HealthCare
OncoMed
Seattle Genetics
Exelixis
Roche/Genentech
Abbvie
Gilead
MedImmune
Macrogenics
Nektar
Leap Therapeutics
Sanofi Genzyme
MSD Oncology
Ono Pharmaceutical
Dainippon Sumitomo Pharma
Taiho Pharmaceutical
Daiichi Sankyo
Lilly
Gilead Sciences
Yakult Honsha
Subject
Gastroenterology,Oncology
Reference105 articles.
1. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS;Yoshino;Ann Oncol,2018
2. Treatment of patients with metastatic colorectal cancer in a real-world scenario: probability of receiving second and further lines of therapy and description of clinical benefit;Tampellini;Clin Colorectal Cancer,2017
3. Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies;Vogel;Cancer Treat Rev,2017
4. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016
5. Colon cancer, version 1.2017, NCCN Clinical Practice Guidelines in Oncology;Benson;J Natl Compr Canc Netw,2017
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献